More drug Targets Drug targets are molecular structures or proteins that pharmaceutical industries are designing drugs to help in preventing or curing diseases. The proteins, pathogenic microorganisms, have distinct purposes in the human body. Since proteins are in different groups due to duplication of the gene, the drug targets are also in different families. The families include the kinases, phosphates, nuclear receptors, and GPCRs (Imming, Sinning, & Meyer 2006). These targets, through clinical effects, specifically interact with the drugs in diagnosing the disease. From this definition approach, there are some constrictions, such as the absence of technique in monitoring the dynamic interaction of proteins and drugs yet diseases, just as life is constantly changing at different instances. This factor has confined the human population to deal with targets as stationary bodies. Secondly, the purpose of medicine omits the tools of pharmacology. Presently, there are averages of 500 therapeutic targets or nucleic acids and proteins that drugs are targeting, but of late, it has moved to 324 are for FDA-approved clinical drugs (Chen, Ji & Chen 2002). In drug design, the human genome helps in finding the genes that have a direct link with different diseases. These genetic components may be due to inheritance or body response to environmental changes thus altering the genomes. Before drug design, researchers must carry out an in-depth analysis of a specific target protein to validate its role. According to Chen, Ji & Chen (2002), the process helps in understanding the disease molecular mechanisms more clearly; consequently, leading to the development of better preventive tests, treatment, and cures. In addition, the process of identifying and validating new drug targets is of immense importance in drug discovery in the pharmaceutical line. Early prediction of the potential applications of proteins as a drug target can effectively fasten the process of drug discovery that targets the protein. The new designs of drugs are less toxic and more potent. Researchers cannot only discover more drug targets with the use of modern computer technology and a better understanding of various disease mechanisms but also discover specific drugs that can interact with both the symptoms and causes of the disease. The mass data analysis in bioinformatics helps unearth the wealth of information that can create a clear understanding of the fundamental biological organisms. Pharmacologists should come up with more drug targets as this will enable the production of a specific drug for a specific disease. Currently, many medicines have more side effects, coupled with a lot of disease resistance to drugs. For instance, tuberculosis (TB) remains a key cause of infectious morbidity and mortality treatment, in spite of the presence of the BCG vaccine and chemotherapy. The mycobacterium TB pathogen causes nearly nine million disease fresh infection cases and about 1.5 – 2 million deaths yearly (Ying 2012, p. 719). With drug-resistant TB, such as multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) on the rise, extensive research is underway to come up with exactly more drug targets that will help in controlling the disease. The TB case is immensely under threat by HIV infection and XDR/MDR-TB; they lower the immune system thus easily increasing the susceptibility of contractin